BBLG earnings analysis
What we found in BBLG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include income statement, balance sheet, cash flow, segment, or MD&A operating results, so revenue, margin, EPS, liquidity, and free-cash-flow trends cannot be assessed. Disclosure controls were deemed effective as of June 30, 2026, with no material internal-control changes reported for the quarter. The most material filing update is the potential Nasdaq delisting risk tied to a $5 million market-value requirement and a 30-business-day compliance period, although the rule was stayed on July 29, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
- No material control changes
- The company reported no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
- No material legal proceedings disclosed
- The company stated that it is not presently a party to legal proceedings that would have a material adverse effect on its business, results of operations, financial condition or cash flows.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Potential Nasdaq delisting
- A new Nasdaq continued-listing rule approved on July 22, 2026 would require at least $5 million of market value of listed securities. The company stated it would not comply if the rule took effect; failure to meet the requirement for 30 consecutive business days could result in suspension and immediate delisting. The SEC stay announced July 29, 2026 temporarily paused the rule pending review.
What they said about what is next.
The provided 10-Q extract contains no quantitative revenue or EPS outlook. The filing refers to the 2025 Form 10-K and current MD&A for additional discussion, but no numeric guidance is disclosed in the provided text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Bone Biologics reported a continued net loss in Q1 2026, with net losses improving by 24.69% YOY, totaling $765,988. Operating expenses decreased significantly by 22.48% primarily due to lower R&D spending, while…
- 10-K · March 2, 2026
- Bone Biologics is a clinical-stage orthobiologics company focused on developing NELL-1/DBM (NB1) for lumbar spinal fusion. The company has advanced from pivotal animal work (37.5% increased fusion frequency at 26 weeks)…
- 10-Q · August 9, 2024
- Bone Biologics reported no revenue for the quarter (Revenues $0) and materially reduced operating spending, producing a smaller net loss of $783,733 (Q2 2024) versus $1,769,238 (Q2 2023). Cash declined to $2,332,068 at…
- 10-Q · May 14, 2024
- Bone Biologics (BBLG) reported Q1 net loss of $865,970 (loss per share $1.31) versus a loss of $3,709,899 (loss per share $55.20) in Q1 2023 — a material reduction in loss driven by a sharp decline in operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BBLG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever